This year had been the year for radiopharmaceuticals, with market projections estimating it would grow to $39 billion by 2032. More patients were being treated by Pluvicto and Lutathera than ever before, and companies advanced their pipelines across a range of targeting moieties, radioisotopes, and novel targets including DLL3 and NTSR1—and that’s not to mention the flood of billion-dollar acquisitions and investments from Novartis, AstraZeneca, Eli Lilly and BMS that strengthened the field! The 6^th Targeted Radiopharmaceuticals Summit Europe was the longest-standing industry-focused meeting, delivering an end-to-end overview of this highly competitive and dynamic landscape.

It uncovered novel target development beyond validated PSMA and SSTR2 to reach more indications, expanded targeting moieties to enhance tumor penetration, and revealed key case studies designing a first in human radiopharmaceutical trial as well as applying dosimetry to optimize dosing. The community explored how Europe could keep up with fast-paced innovation by reaching regulatory clarity while analysing the US-Europe intersection across pressing clinical and supply chain challenges to keep your global trials moving. Bringing together insights from the leading radiopharmaceutical minds across pharma, biotech, academia, and clinicians from discovery, preclinical, clinical, CMC and supply chain it was an opportunity to network and learn from the experts.

World-class speakers were gathered to address the most exciting opportunities and challenges spanning novel targeting mechanisms, alpha vs. beta emitters, nuclear medicine clinical expertise, isotope supply, European logistics chains, as well as pricing and reimbursement—don’t miss the biggest edition of the 6^th Targeted Radiopharmaceuticals Summit to date!